论文部分内容阅读
将 40例恶性淋巴瘤患者随机分为治疗组 :用胸腺肽 10 0 mg/ d静滴 ,合并使用常规化疗方案 (包括 CHOP、EACOP方案 ) ;对照组 :仅使用常规化疗方案。结果 :治疗组有效率 70 % ,对照组有效率 6 0 % (P>0 .0 5 )。治疗组治疗后 Ig G、CD3、CD4、CD4/ CD8、NK细胞活性均明显高于治疗前 (P<0 .0 5 )。说明 :胸腺肽可调节 T淋巴细胞功能 ,提高 Ig G水平、CD3+、CD4+细胞数及 NK细胞活性 ,降低 CD8+细胞数。且无明显副反应 ,大剂量胸腺肽辅助治疗 NHL 患者 ,具有一定临床意义
Forty patients with malignant lymphoma were randomly divided into treatment group: thymosin 10 0 mg / d, combined with conventional chemotherapy (including CHOP, EACOP regimen); control group: only conventional chemotherapy regimen. Results: The effective rate was 70% in the treatment group and 60% in the control group (P> 0.05). After treatment, Ig G, CD3, CD4, CD4 / CD8 and NK cell activity in treatment group were significantly higher than before treatment (P <0.05). Description: Thymosin can regulate the function of T lymphocytes, increase Ig G level, CD3 +, CD4 + cells and NK cell activity, reduce the number of CD8 + cells. And no obvious side effects, high-dose thymosin adjuvant NHL patients, has some clinical significance